Tarsus Pharmaceuticals, Inc.
TARS
Rangering i aksjer
#4650
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Aksjekurs
$70.00
Markedsverdi
$3.28B
Endring (1 dag)
2.84%
Endring (1 år)
-4.02%
Land
US
Handel Tarsus Pharmaceuticals, Inc. (TARS)
Kategori
Healthcare
EPS for Tarsus Pharmaceuticals, Inc. (TARS)
EPS per June 2026 TTM: $-1.09
Ifølge de siste økonomiske rapportene og aksjekursen til Tarsus Pharmaceuticals, Inc. er selskapets nåværende EPS (TTM) $-1.09. Ved slutten av 2023 hadde selskapet en EPS på $-4.62, en økning sammenlignet med EPS-en i 2022 som var $-2.52.
EPS-historikk for Tarsus Pharmaceuticals, Inc. fra 2018 til 2026
EPS ved slutten av hvert år
| År | EPS | Endre |
|---|---|---|
| 2026 (TTM) | $-1.09 | -64.50% |
| 2024 | $-3.07 | -33.55% |
| 2023 | $-4.62 | 83.33% |
| 2022 | $-2.52 | 276.12% |
| 2021 | $-0.67 | -49.24% |
| 2020 | $-1.32 | 450.00% |
| 2019 | $-0.24 | -22.58% |
| 2018 | $-0.31 | 0.00% |
EPS for lignende selskaper eller konkurrenter
| Selskap | EPS | EPS-forskjell | Land |
|---|---|---|---|
| $17.32 | -1,688.99% |
US
|
|
| $-7.98 | 632.11% |
US
|
|
| $-5.29 | 385.32% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -2,644.95% |
NL
|
